Accuray to Showcase Clinical Utilization and Adoption of its Latest Advanced Product Platforms at ASTRO 2013

 Accuray to Showcase Clinical Utilization and Adoption of its Latest Advanced
                       Product Platforms at ASTRO 2013

World's Largest Annual Gathering of the Radiation Oncology Community Provides
Multiple Opportunities to Learn about the CyberKnife® M6™ Series and the
TomoTherapy® H™ Series Systems

PR Newswire

SUNNYVALE, Calif. and ATLANTA, Sept. 22, 2013

SUNNYVALE, Calif. and ATLANTA, Sept. 22, 2013 /PRNewswire/ -- ASTRO 2013 --
Accuray Incorporated (Nasdaq: ARAY) announced today its momentum in gaining
adoption for both the new CyberKnife® M6™ Series and TomoTherapy® H™ Series
Systems at the 55th Annual American Society for Radiation Oncology (ASTRO)
Meeting taking place at the Georgia World Congress Center in Atlanta. Through
presentations from leading radiation oncology practitioners and product
demonstrations, attendees can gain further knowledge on the clinical
capabilities of theCyberKnife M6 Series and TomoTherapy H Series Systems
introduced at last year's ASTRO meeting.

Adoption of Accuray's latest advanced product platforms continues to grow,
with many cancer centers in the U.S. and in Europe already investing in the
technology. U.S. centers include the University of Pittsburgh Medical Center
in Pennsylvania, Tulsa Cancer Institute of Oklahoma, Lancaster General Health
in Pennsylvania, Spokane CyberKnife & Radiation Oncology Center in Washington
and University of Arkansas Medical Sciences in Little Rock. Centers in Europe
and Asia include, the European CyberKnife Center Munich-Grosshadern (ECZM) in
Munich, Germany, Heidelberg University Hospital in Germany, Erasmus Medical
Center (MC), in Rotterdam, the Netherlands, the Centre Oscar Lambret in Lille,
France and The Severance Hospital, Yonsei University Healthcare System in
Seoul, Korea.

These institutions have successfully implemented the new CyberKnife and
TomoTherapy Systems and are experiencing significant benefits, including
reduced treatment times, improved treatment plan quality, expanded patient
treatment options for the CyberKnife M6 System, and reduced treatment planning
time with the TomoHDA System.

"We have seen firsthand that the non-coplanar beam geometry of the CyberKnife
M6 System allows us to create high-quality, high-dose distributions that can
be delivered with extreme accuracy over a minimum number of treatments
allowing us to minimize side effects and preserve our patients' quality of
life," said Jeffrey S. Eshleman, M.D., Director of Radiation Oncology, Ann B.
Barshinger Cancer Institute of Lancaster General Health in Pennsylvania. "We
are focused on providing the most effective and efficient SRS/SBRT treatment
option and the CyberKnife System has excelled in its ability to track and
treat moving targets while sparing nearby critical structures and healthy
tissue."

"In its first three months of clinical use at our center, the TomoHDA System
has proven to be a versatile and efficient addition to our department," said
Prof. Eric Lartigau, M.D., Ph.D., Centre Oscar Lambret, Lille, France. "The
system allows rapid treatment planning and high-precision dose delivery, a
combination of features that lends itself well to breast cancer cases and
helps improve overall quality, patient throughput and workflow for the
department."

"In an effort to enhance the capabilities of the TomoTherapy and CyberKnife
Systems, our guiding mission is always to provide patients with the best
possible treatment outcomes," said Joshua H. Levine, president and chief
executive officer of Accuray. "The feedback we have received from leading
radiation oncology practitioners validates the decision to further invest in
our unique product offerings. We look forward to our invaluable collaborators
informing colleagues of their experiences and learnings to-date at this year's
ASTRO meeting."

There will be many opportunities to learn about Accuray's advanced radiation
oncology treatment solutions at the 2013 ASTRO annual meeting, including:

Clinical research presentations: Clinical presentations will be delivered in
scientific sessions highlighting clinical outcomes obtained with real-time
tracking of target motion and automatic correction of beam aim with Accuray's
CyberKnife System. Additionally, presentations will be delivered on the
clinical benefits of exceptional treatment plan quality and accurate
megavoltage CT-guided patient setup with the TomoTherapy System.

Industry expert theater: Accuray will host a symposium at the ASTRO Industry
Expert Theater titled, "Accuray: Dynamic Technology in Motion," presented by
Alexandra Jensen, M.D., MSc., University of Heidelberg and Prof. Alexander
Muacevic, M.D., European CyberKnife Center Munich on Sunday, September 22 from
12:45 p.m. – 1:45 p.m. ET in the Exhibit Hall. These luminaries will share
firsthand perspectives on the clinical benefits of the new CyberKnife M6
Series and TomoTherapy H Series Systems. Lunch will be served. 

In-booth presentations and product demonstrations: While the exhibit hall is
open, Accuray will offer in-booth presentations (booth #1842) and product
demonstrations on new features including VoLO™ Planning and TomoEDGE™ Dynamic
Jaws for the TomoHDA System and the Multileaf Collimator (MLC) for the
CyberKnife M6 System. The exhibit hall will be open Sunday, September 22 –
Tuesday, September 24 from 10:00 a.m. – 5:00 p.m. ET each day. For those
interested in registering for product demonstrations in advance, please visit
http://accuraybooth1842atlanta.com/.

Investor meeting: Accuray's management team will host a breakfast meeting,
from 7:00 a.m. to 9:00 a.m. ET on Monday, September 23 at the OMNI Hotel, 100
CNN Center Atlanta, in the International Ballroom F. The presentation will
provide a review of Accuray's leading-edge technology platforms of radiation
therapy and radiosurgery treatments. Attendees are asked to register online:
https://www.regonline.com/Register/Checkin.aspx?EventID=1281872. A live
webcast of the presentation will be available online from the Investor
Relations page of the Company's website at http://www.accuray.com/investors.

Follow the Accuray Twitter handle, @Accuray, for real-time updates from the
ASTRO show floor. To schedule a briefing with an Accuray executive, please
contact Rebecca Phillips, rphillips@accuray.com or +1 (408) 242-3831.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells precise, innovative tumor treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range
of radiation therapy and radiosurgery treatments. For more information, please
visitwww.accuray.com.

Safe Harbor Statement

Statements made in this press release that are not statements of historical
fact are forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are not limited
to adoption of new technologies, clinical experience, clinical applications,
clinical results, and the Company's leadership position in radiation oncology
innovation and the Company's leadership position in radiation oncology
innovation. Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from expectations,
including risks detailed from time to time under the heading "Risk Factors" in
the company's report on Form10-K filed on August29, 2013, and as updated
periodically by our other filings. Forward-looking statements speak only as
of the date the statements are made and are based on information available to
the Company at the time those statements are made and/or management's good
faith belief as of that time with respect to future events. The Company
assumes no obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent required by
applicable securities laws. Accordingly, investors should not place undue
reliance on any forward-looking statements.

SOURCE Accuray Incorporated

Website: http://www.accuray.com
Contact: Rebecca Phillips, Public Relations Manager, Accuray, +1 (408)
716-4773, rphillips@accuray.com, or Helen Shik, Schwartz MSL, +1 (781)
684-0770, Accuray@schwartzmsl.com
 
Press spacebar to pause and continue. Press esc to stop.